RecruitingPhase 1NCT06840886
A Study of PHST001 in Advanced Solid Tumors
Studying Adenocarcinoma of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pheast Therapeutics
- Intervention
- PHST001(biological)
- Enrollment
- 272 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (20)
- Precision NextGen Oncology & Research Center, Beverly Hills, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Stanford University School of Medicine, Palo Alto, California, United States
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver, Colorado, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
- START Center for Cancer Research - Midwest, Grand Rapids, Michigan, United States
- START Center for Cancer Research - Long Island New York, Lake Success, New York, United States
- Mount Sinai, New York, New York, United States
- Duke Cancer Institute, Durham, North Carolina, United States
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- START Center for Cancer Research - Texas, Fort Worth, Texas, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06840886 on ClinicalTrials.govOther trials for Adenocarcinoma of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07523529Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsBeijing Biotech
- RECRUITINGNCT07100288Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian CancerComplejo Hospitalario Universitario Insular Materno Infantil
- RECRUITINGPHASE2NCT06730347A Study of Lorigerlimab in Participants With Advanced Solid TumorsMacroGenics
- RECRUITINGPHASE2NCT05500391Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringCentre Oscar Lambret
- RECRUITINGPHASE1, PHASE2NCT05922930Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic CancerM.D. Anderson Cancer Center
- RECRUITINGPHASE3NCT05601700Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)Ente Ospedaliero Ospedali Galliera
- ACTIVE NOT RECRUITINGPHASE2NCT05335993A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.CanariaBio Inc.
- RECRUITINGNCT03452774SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryMassive Bio, Inc.